Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC

Date
2021
Author
Gladkov, O.
Kilickap, S.
Sezer, A.
Gumus, M.
Bondarenko, I.
Ozguroglu, M.
Gogishvili, M.
Turk, H. M.
Cicin, I.
Bentsion, D.
Clingan, P.
Sriuranpong, V.
Rizvi, N.
Li, S.
Lee, S.
Makharadze, T.
Paydas, S.
Nechaeva, M.
Seebach, F.
Weinreich, D. M.
Yancopoulos, G. D.
Gullo, G.
Lowy, I.
Rietschel, P.
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/171524
Collections